loading page

The Use of Ivabradine in a Patient with Idiopathic Ventricular Arrhythmia Originating from the Left Ventricular Summit
  • +2
  • Göksel Cinier,
  • Mert Hayıroğlu,
  • Kazim Ozcan,
  • Ahmet TEKKESİN,
  • Kadir Gurkan
Göksel Cinier
Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
Author Profile
Mert Hayıroğlu
Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
Author Profile
Kazim Ozcan
Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
Author Profile
Ahmet TEKKESİN
Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
Author Profile
Kadir Gurkan
Dr Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital
Author Profile

Abstract

Idiopathic ventricular arrhythmias (VA) are common and treatment options include anti-arrhythmic drugs (AAD) or catheter ablation. Patients presenting with idiopathic VA which is originating from the left ventricular summit (LVS) poses a particular challenge as the success for catheter ablation is low and AAD’s may not be used long-term due to side effects. Ivabradine is an inhibitor of funny current (If) in cardiac pacemaker cells by blocking hyperpolarization-activated cyclic nucleotide-gated (HCN) and recommended for the treatment of heart failure with reduced ejection fraction and stable coronary artery disease. Recently, several cases described patients with atrial and junctional ectopic tachycardias who were successfully treated with ivabradine. In the present case, we reported the use of ivabradine in the treatment of idiopathic VA which was originated from the LVS and was resistant to multiple AAD’s and catheter ablation.